Twinbeech Capital LP Janux Therapeutics, Inc. Transaction History
Twinbeech Capital LP
- $4.95 Billion
- Q1 2025
A detailed history of Twinbeech Capital LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Twinbeech Capital LP holds 77,437 shares of JANX stock, worth $1.97 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
77,437Holding current value
$1.97 Million% of portfolio
0.04%Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
194Shares Held
57.3MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$284 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$117 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$92.8 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$84.6 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$59.5 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.06B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...